The Influence Of Estrogen To The Prophylaxis Of Bone Metastases In Breast Carcinoma Of Zoledronate

Objective:To study the influence of estrogen to the prophylaxis of bone metastases in breast carcinoma of zoledronate. Methods:216cases of breast cancer patient who accepted modified radical mastectomy,chernotherapy and the prophylaxis of zoledronate collected between January2006to December2009,and divided into two groups according to estrogen:(1) The groups of estrogen at a low-level included39cases.(2) The groups of estrogen at a normal level included177cases.Two groups divided into4subunits according to breast cancer classification and all accepted the therapy of zoledronate,then with clinical follow-up for3to5years until progressive disease (include neoplasm recurrence,bone metastases and other neoplasm metastasis,et al.).Results:The patients with bone metastases situation:(1) The comparison between the two groups:E2I group with6cases and bone E2in the normal group with57cases of bone metastases, compared between two groups was statistically difference.(x2=4.38,P<0.05)(2) The bone metastases of luminal A contained1cases of estrogen at a low-level and20cases of estrogen at a normal level,and had a statistical difference between it.(x2=4.29,P<0.05)(3) The bone metastases of luminal B contained2cases of estrogen at a low-level and18cases of estrogen at a normal level,and had a statistical difference between it.(x2=430,P<0.05)(4) The bone metastases of Her-2contained2cases of estrogen at a low-level and13cases of estrogen at a normal level,and had no statistical difference between it.(x2=0.13,.P>0.05)(5)The bone metastases of triple negative breast carcinoma included1cases of estrogen at a low-level and6cases of estrogen at a normal level, and had no statistical difference between it.(x2=0.01,p>0.05)(6) Compared the bone metastases between4subunits in estrogen at a low-level group suggested that had no statistical difference between it.(x2=2.31,P>0.05) Conclusion:The patients for progestational hormone receptor-positive breast cancer, premenopausal low estrogen levels used azole phosphonic acid to prevent bone metastases have significant clinical benefit, estrogen levels of other types of breast cancer used to effect a phosphonic acid curative effect is not obvious.